Core Points - Avalon GloboCare Corp. announced the issuance of a new standard patent for its CAR-T and CAR-Natural Killer (NK) cell technology in Hong Kong, marking a significant milestone in its global intellectual property strategy [1][2][3] - The patent, effective from February 21, 2020, provides 20 years of protection for the company's proprietary technology, reinforcing its competitive position in the field of cell-based immunotherapy [2][3] - The patented technology aims to enhance the manufacturing, expansion, survival, and therapeutic efficacy of CAR-T and CAR-NK cells, which is crucial for advancing treatment options in hematologic malignancies [3][7] Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and advancing intellectual property in cellular therapy, including the marketing of the KetoAir™ breathalyzer device [4] - The company is also engaged in the development of additional diagnostic uses for its breathalyzer technology, which is registered as a Class I medical device with the U.S. FDA [4] - Avalon continues to expand its intellectual property portfolio through existing patent applications and also owns and operates commercial real estate [4]

Core Viewpoint - Avalon GloboCare Corp. has entered into a definitive agreement with Qi Diagnostics to co-develop a VOC nanosensor-based point-of-care cannabis breathalyzer aimed at enhancing public safety and supporting real-time detection of cannabis-impaired driving [1][2][3] Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and is advancing intellectual property in cellular therapy [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device [4] Strategic Collaboration - The collaboration involves Avalon, its subsidiary Q&A Distribution, LLC, and Qi Diagnostics to jointly design, validate, and develop a prototype for the cannabis breathalyzer device [2] - This partnership aims to combine Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology to create a non-invasive cannabis detection solution [3] Public Health Impact - The cannabis breathalyzer is intended to support law enforcement and workplace safety by providing a real-time detection solution for cannabis impairment [3]

Core Viewpoint - Avalon GloboCare Corp. has entered into a definitive agreement with Qi Diagnostics Limited to co-develop a VOC nanosensor-based point-of-care cannabis breathalyzer aimed at enhancing public safety and supporting real-time detection of cannabis-impaired driving [1][2][3] Company Overview - Avalon GloboCare Corp. (NASDAQ: ALBT) specializes in precision diagnostic consumer products and is advancing intellectual property in cellular therapy [4] - The company is currently marketing the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device [4] Strategic Collaboration - The collaboration involves Avalon, its subsidiary Q&A Distribution, LLC, and Qi Diagnostics to jointly design, validate, and develop a prototype for the cannabis breathalyzer device [2] - This partnership aims to combine Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology to provide a non-invasive cannabis detection solution [3]

Core Viewpoint - Avalon GloboCare Corp. and YOOV Group Holding Limited have announced a proposed merger, aiming to create a publicly-traded company focused on AI-driven business automation solutions [1][2]. Company Overview - Avalon GloboCare Corp. is a commercial-stage company specializing in precision diagnostic consumer products and cellular therapy, currently marketing the KetoAir™ breathalyzer device, which is registered as a Class I medical device with the U.S. FDA [6]. - YOOV Group Holding Limited is an AI-as-a-Service platform that specializes in intelligent business automation, allowing businesses to optimize operations without extensive resources or technical expertise [4]. Merger Details - The merger involves Nexus MergerSub Limited, a wholly owned subsidiary of Avalon, merging with YOOV, with YOOV becoming a wholly owned subsidiary of Avalon [2]. - The merger is subject to stockholder approval from Avalon and the Nasdaq Stock Market's approval for YOOV's listing post-merger [3]. Additional Offerings - YOOV extends its services into financial and insurance sectors through subsidiaries YOOV Capital Limited and YOOV Insurance Services Limited, enhancing its ecosystem with credit evaluation and insurance brokerage services [5].

Core Insights - Avalon GloboCare Corp. has been granted a patent for its CAR-T and CAR-NK cell technology by the China National Intellectual Property Administration, marking a significant milestone in its global intellectual property strategy [1][2][3] Intellectual Property Expansion - The newly issued Chinese patent, co-developed with Arbele Limited, enhances Avalon's intellectual property portfolio and is already protected in the U.S. and other territories under the Patent Cooperation Treaty [2] - The patent covers technology aimed at improving the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-NK cells, providing 20 years of protection from the issuance date [3] Commitment to Innovation - Avalon emphasizes its commitment to advancing immunotherapy technologies, as stated by CEO David Jin, highlighting the importance of this patent in strengthening the company's position in cell-based immunotherapy [3]